Ethische Aspekte der medikamentösen Behandlung dementer Patienten
暂无分享,去创建一个
[1] C. Filley,et al. Ethical concerns in the use of palliative drug treatment for Alzheimer's Disease. , 1996, The Journal of neuropsychiatry and clinical neurosciences.
[2] P. Whitehouse,et al. Emergency Research and Research Involving Subjects with Cognitive Impairment: Ethical Connections and Contrasts , 1997, Journal of The American Geriatrics Society.
[3] R J Harvey,et al. Drug treatments for Alzheimer's disease , 1997, BMJ.
[4] D. Knopman. Metrifonate for Alzheimer's disease , 1998, Neurology.
[5] G. Wilcock,et al. The cholinergic hypothesis of Alzheimer’s disease: a review of progress , 1999, Journal of neurology, neurosurgery, and psychiatry.
[6] M. Lachs,et al. Should patients with Alzheimer's disease be told their diagnosis? , 1992, The New England journal of medicine.
[7] G. Naglie,et al. The Use of Medications for Cognitive Enhancement , 2001, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[8] A. Roses,et al. The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. , 1997, JAMA.
[9] P. Whitehouse,et al. Guidelines for Addressing Ethical and Legal Issues in Alzheimer Disease Research: A Position Paper , 1994, Alzheimer disease and associated disorders.
[10] P. Whitehouse,et al. Fairhill Guidelines on Ethics of the Care of People With Alzheimer's Disease: A Clinical Summary * , 1995, Journal of the American Geriatrics Society.
[11] R. Berghmans. Ethical Hazards of the Substituted Judgement Test in Decision Making Concerning the End of Life of Dementia Patients , 1997, International journal of geriatric psychiatry.
[12] A. Burns,et al. New drugs for Alzheimer's disease , 1999, British Journal of Psychiatry.
[13] J. Vollmann. Aufklärung und Einwilligung in der Psychiatrie , 2000 .
[14] J. Oldham,et al. Uninformed decisionmaking. The case of surrogate research consent. , 1997, The Hastings Center report.
[15] S. Ferris,et al. Suicide in two patients with a diagnosis of probable Alzheimer disease. , 1999, Alzheimer disease and associated disorders.
[16] G. Sachs. Dementia and the Goals of Care , 1998, Journal of the American Geriatrics Society.
[17] N. Kass,et al. Trust, The fragile foundation of contemporary biomedical research. , 1996, The Hastings Center report.
[18] J. Magaziner,et al. Proxies' Decisions About Clinical Research Participation for Their Charges , 1997, Journal of the American Geriatrics Society.
[19] D. Knopman,et al. Clinical research designs for emerging treatments for Alzheimer disease: moving beyond placebo-controlled trials. , 1998, Archives of neurology.
[20] K. Glass,et al. Proposed Guidelines for the Participation of Persons with Dementia as Research Subjects , 2015, Perspectives in biology and medicine.
[21] J. Karlawish,et al. What is the Quality of the Reporting of Research Ethics in Publications of Nursing Home Research? , 1999, Journal of the American Geriatrics Society.
[22] N. Cutler,et al. Recent Developments in the Drug Treatment of Alzheimer’s Disease , 1999, Drugs & aging.
[23] H. Lauter,et al. Dürfen Ärzte mit Demenzkranken forschen? Analyse des Problemfeldes Forschungsbedarf und Einwilligungsproblematik , 1995 .
[24] C. Cassel,et al. Treatment choices at the end of life: a comparison of decisions by older patients and their physician-selected proxies. , 1989, The Gerontologist.
[25] R. Evans,et al. Pharmacologic treatment of cognition in Alzheimer's dementia , 1998, Neurology.
[26] R. Schulz,et al. The perspective of the patient with Alzheimer's disease: a neglected dimension of dementia research. , 1993, The Gerontologist.
[27] S. Post,et al. Future scenarios for the prevention and delay of Alzheimer disease onset in high-risk groups. An ethical perspective. , 1999, American journal of preventive medicine.
[28] D. Melzer. New drug treatment for Alzheimer's disease: lessons for healthcare policy , 1998, BMJ.
[29] L. Schneider,et al. Long-term tacrine (Cognex) treatment , 1996, Neurology.
[30] Slowing the progression of Alzheimer disease: ethical issues. , 1997, Alzheimer disease and associated disorders.
[31] H. Vanderpool,et al. False data & the therapeutic misconception: two urgent problems in research ethics. False data and last hopes: enrolling ineligible patients in clinical trials. , 1987, The Hastings Center report.
[32] S. Post. The Fear of Forgetfulness: A Grassroots Approach to an Ethics of Alzheimer’s Disease , 1998, The Journal of Clinical Ethics.
[33] M N Rossor,et al. Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease. A longitudinal prospective study. , 1998, Brain : a journal of neurology.
[34] J. Karlawish,et al. Is the placebo control obsolete in a world after donepezil and vitamin E? , 1998, Archives of neurology.
[35] Academisch Ziekenhuis. Cholinesteraseremmers bij de ziekte van Alzheimer: voorlopige aanbevelingen voor de praktijk , 1998 .
[36] S. Gauthier,et al. Rivastigmine for Alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications. , 2000, Clinical Therapeutics.
[37] P. Whitehouse,et al. Emerging Antidementia Drugs: A Preliminary Ethical View , 1998, Journal of the American Geriatrics Society.
[38] J. Tenney,et al. Informed consent by proxy. An issue in research with elderly patients. , 1986, The New England journal of medicine.
[39] K. Davis. Cholinesterase Inhibitors in Alzheimer's Disease , 1994, Neuropsychopharmacology.
[40] M. Ratain,et al. Perceptions of cancer patients and their physicians involved in phase I trials. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] M. Farlow. New treatments in Alzheimer disease and the continued need for placebo-controlled trials. , 1998, Archives of neurology.
[42] P S Appelbaum,et al. False hopes and best data: consent to research and the therapeutic misconception. , 1987, The Hastings Center report.
[43] K. Davis,et al. The search for disease-modifying treatment for Alzheimer's disease , 1997, Neurology.